2Osborne CK. Adjuvant endocrine therapy. [M].Harris,Lippman, Morrow, et al. Diseases of the breast. 3rd Ed.USA. Lippincott: Williams & Wilkins,2004:865-891.
5Janni W,Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety [J]. Cancer Treat Rev, 2010,36(3): 249-261.
6Jones SE, Hasenburg A, Rae D, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane ad- juvant muhinational) prospective randomized phase m trial in hormone sensitive postmenopausal early breast cancer [C]. San Antonio TX: 31st Annual San Antonio Breast Cancer Symposium, 2008.
7Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastro- zole and tamoxifen as adjuvant treatment for early-stage breast cancer: lO0-month analysis of the ATAC trial[J]. Lancet Oncol, 2008,9( 1 ): 45-53.
8Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with ear- ly breast cancer: first results of the ATAC randomised trial [J]. Lancet, 2002, 359(9324): 2131-2139.
9Thurlimann B, Keshaviah A, Coates AS, et al. A com- parison of letrozole and tamoxifen in postmenopausal women with early breast cancer [J]. N Engl J Med, 2005,353 (26): 2747-2757.
10Joerger M, Thurlimann B. Update of the BIG 1-98 trial: where do we stand?[J]. Breast, 2009, 18(Suppl 3): s78-s82.
